Search

Your search keyword '"Qiao, Shu-Bin"' showing total 276 results
Start Over Author "Qiao, Shu-Bin" Language english
276 results on '"Qiao, Shu-Bin"'

15. Effect of sex difference in clinical presentation (stable coronary artery disease vs unstable angina pectoris or non‐ST‐elevation myocardial infarction vs ST‐elevation myocardial infarction) on 2‐year outcomes in patients undergoing percutaneous coronary intervention

Author

Tang, Xiao‐Fang, Song, Ying, Xu, Jing‐Jing, Ma, Yuan‐Liang, Zhang, Jia‐Hui, Yao, Yi, He, Chen, Wang, Huan‐Huan, Jiang, Ping, Jiang, Lin, Liu, Ru, Gao, Zhan, Zhao, Xue‐Yan, Qiao, Shu‐Bin, Xu, Bo, Yang, Yue‐Jin, Gao, Run‐Lin, and Yuan, Jin‐Qing

Published
2018
Full Text
View/download PDF

22. Long-term follow-up of antithrombotic management patterns in patients with acute coronary syndrome in China

Author

Han, Xiao-Ning, Qiao, Shu-Bin, Ge, Jun-Bo, Han, Ya-Ling, Chen, Ji-Yan, Yuan, Zu-Yi, Yu, Bo, Jiang, Jie, and Huo, Yong

Subjects
Antithrombotic management patterns, Real-world, Observational study, Acute coronary syndrome, Antithrombotic agents, Research Article
Abstract

Objective To describe the long-term antithrombotic management patterns (AMPs) and clinical outcomes of Chinese patients with acute coronary syndrome (ACS). Methods This was an observational, multicenter, longitudinal cohort extension study of Chinese patients who had completed the EPICOR Asia 2-year follow-up study post-hospitalization for an ACS event. Changes in AMP and clinical outcomes for up to 5 years post-ACS event were evaluated. Results Overall, 2334 patients with ACS were enrolled at 49 sites. The mean age was 61.6 years and 76.3% were men. By study end, 2093 patients completed the 3-year follow-up. At baseline (2 years post-ACS event), 72.4% of patents received one antiplatelet (AP) medication, with aspirin being the preferred one. A small proportion of patients (21.5%) was treated with two or more APs (2+ AP), and even fewer patients (6.1%) did not receive any AP medication at baseline. Upon study completion, the proportion of patients without AP therapy increased to 13.6%, while the percentage of patients on one AP and 2+ AP decreased to 69.3% and 17.1%, respectively. Numerically, a higher incidence of clinical events (composite of all-cause mortality, myocardial infarction, stroke) was observed for the 2+ AP (13.2%) subgroup than for the no AP (10.5%) and one AP (8.6%) subgroups. Furthermore, the 2+ AP subgroup exhibited the greatest number of bleeding events, outpatient visits, and hospitalization rates. Unlike myocardial infarction or stroke, bleeding events prompted an adjustment in AMP. Conclusion Most patients in China received at least one AP medication up to 5 years after an ACS event.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results